3 Forgotten Small-Caps Hiding in Biocomputing, Nuclear, and AI Power

Gartner says 40% of AI data centers will be strangled by power shortages within the next year. Microsoft, Amazon, Meta, and Google are signing 17 to 20 year nuclear contracts just to keep the lights on. And yet, here you are, still reading about Nvidia. Respectfully: look up.

The social sentiment from Felix and Friends (Goat Academy) on YouTube made a sharp point this week: only three companies operate deregulated nuclear fleets capable of signing private power contracts with hyperscalers. That's not a crowded trade. That's a velvet rope. One of those names is $CSWC... wait, wrong rabbit hole. The one you actually want is $NNE (Nano Nuclear Energy), a pre-revenue but NASDAQ-listed micro-cap that is developing portable microreactors for off-grid industrial and data center use. It has no revenue yet, which is exactly why almost nobody owns it. The catalyst: a single commercial partnership announcement with any tier-2 data center operator would be a watershed moment for a company this size. Bear case is real, because pre-revenue is pre-revenue, and this is a binary bet. Keep position sizes honest.

The second pick is $NXRT... actually, let's go somewhere weirder. Meet $POWL (Powell Industries), a Houston-based maker of electrical switchgear and power distribution equipment. Market cap sits comfortably under $2 billion. Nobody talks about this company. It builds the physical hardware that routes electricity inside data centers, industrial plants, and utility substations. With AI infrastructure spending accelerating and data center power demand expected to double in two years per Felix and Friends, POWL is the unsexy plumbing play that actually makes the whole system work. Catalyst: any large data center buildout announcement from a major hyperscaler implicitly means more switchgear orders. The bear case is margin pressure from steel and copper input costs, especially with tariff volatility hanging around.

Third on the list is $HIMS (Hims and Hers Health), which might be the most under-appreciated mid-cap sitting below $4 billion market cap right now. Bernstein Private Wealth flagged this week that the smart diversification trade in AI is moving toward healthcare innovation end-users, not just infrastructure. HIMS is building a telehealth and personalized medicine platform at exactly the moment mRNA and AI-driven diagnostics (see: the Moderna and Merck melanoma vaccine trial data blowing up this week) are proving that individualized treatment is the future. Catalyst: any partnership with a diagnostics or pharma name riding the mRNA wave could reprice this stock fast. Bear case: it carries regulatory risk and still burns cash.

Three companies, three completely different angles on the same macro story: AI is eating the world, and the world does not have enough power, infrastructure, or healthcare capacity to keep up. The obvious trades are already obvious. These are the ones that aren't yet.